actabiomedicaActa Biomedica ScientificaActa Biomedica Scientifica2541-94202587-9596Scientific Centre for Family Health and Human Reproduction Problems10.29413/ABS.2024-9.1.2actabiomedica-4594Research ArticleВНУТРЕННИЕ БОЛЕЗНИINTERNAL DISEASESРоль лизофосфатидной кислоты и её рецепторов в патогенезе бронхиальной астмыLysophosphatidic acid and itsreceptors: Role in bronchial asthma pathogenesishttps://orcid.org/0000-0001-5018-0271КытиковаО. Ю.KytikovaO. Yu.

Кытикова Оксана Юрьевна – доктор медицинских наук, старший научный сотрудник лаборатории восстановительного лечения, 

690105, г. Владивосток, ул. Русская, 73г

Oxana Yu. Kytikova – Dr. Sc. (Med.), Senior Research Officer at the laboratory of  Rehabilitation Treatment,

Russkaya str. 73G, Vladivostok 690105

kytikova@yandex.ruhttps://orcid.org/0000-0002-6058-201XНовгородцеваТ. П.NovgorodtsevaT. P.

Новгородцева Татьяна Павловна – доктор биологических наук, профессор, заместитель директора по научной работе, главный научный сотрудник лаборатории биомедицинских исследований, 

690105, г. Владивосток, ул. Русская, 73г

Tatyana P. Novgorodtseva – Dr. Sc. (Biol.), Professor, Deputy Director for Science, Chief Research Officer at the Laboratory of Biomedical Research, 

Russkaya str. 73G, Vladivostok 690105

nauka@niivl.ruhttps://orcid.org/0000-0003-4130-8899ДенисенкоЮ. К.DenisenkoYu. K.

Денисенко Юлия Константиновна – доктор биологических наук, заведующая лабораторией биомедицинских исследований, 

690105, г. Владивосток, ул. Русская, 73г

Yulia K. Denisenko – Dr. Sc. (Biol.), Head of the Laboratory of Biomedical Research, 

Russkaya str. 73G, Vladivostok 690105

karaman@inbox.ruВладивостокский филиал ФГБНУ «Дальневосточный научный центр физиологии и патологии дыхания» – Научно-исследовательский институт медицинской климатологии и восстановительного леченияVladivostok Branch, Far Eastern Scientific Centre of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitation Treatment202425032024911222Copyright © Кытикова О.Ю., Новгородцева Т.П., Денисенко Ю.К., 20242024Кытикова О.Ю., Новгородцева Т.П., Денисенко Ю.К.Kytikova O.Y., Novgorodtseva T.P., Denisenko Y.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actabiomedica.ru/jour/article/view/4594

Лизофосфатидная кислота (LPA, lysophosphatidic acid) является биологически активным липидным медиатором, регулирующим ряд сигнальных путей, вовлечённых в патогенез бронхиальной астмы (БА). Интерес к изучению взаимоотношений LPA с LPA-рецепторами (LPARs, lysophosphatidic acid receptors) и  ионными каналами с  транзиторным рецепторным потенциалом (TRP, transient receptor potential) обусловлен их  ролью в  инициации и  развитии бронхиальной обструкции, что предполагает разработку новых эффективных стратегий лечения БА через блокирование синтеза LPA и/или регуляции активности лиганд-рецепторного взаимоотношения.

Цель обзора

Цель обзора. Обобщить представления о роли лизофосфатидной кислоты и её рецепторов в патогенезе бронхиальной астмы на основании анализа статей, опубликованных на английском языке в период с 2020 по 2023 г. в базе данных PubMed.

Заключение

Заключение. В данном обзоре обобщены последние литературные данные о химической структуре, путях биосинтеза и рецепторах LPA. Представлена информация о роли LPA, LPARs и TRP-каналов в патогенезе БА. Обобщены терапевтические стратегии БА, нацеленные на  LPA, LPARs и  TRP-каналы. Данный обзор подчёркивает не только новый взгляд на понимание механизмов инициации астматических реакций, но и возможные способы управления ими на этапе коррекции их развития.

Lysophosphatidic acid (LPA) is a biologically active lipid mediator that regulates a number ofsignaling pathways involved in the pathogenesis of bronchial asthma. Attention to studying the relationship of LPA with LPA receptors (LPARs) and ion channels with transient receptor potential (TRP) is caused by their role in the initiation and development of bronchial obstruction, which suggests the development of new effective strategies for the treatment of bronchial asthma through blocking LPA synthesis and/or regulation of the activity of the ligand-receptor relationship.

The aim of the review

The aim of the review. To summarize ideas on the role of lysophosphatidic acid and its receptors in the pathogenesis of bronchial asthma based on the analysis of articles published in English in 2020–2023 from the PubMed database.

Conclusion

Conclusion. The review summarizes recent literature data on the chemical structure, biosynthetic pathways and LPA receptors. It presents the information on the role of LPA, LPARs andTRP channels inthepathogenesis of bronchial asthma; summarizes the bronchial asthma therapeutic strategies targeting LPA, LPARs, andTRP channels. The review highlights not only a new perspective on understanding the mechanisms of initiation of asthmatic reactions, but also possible ways to manage them at the stage of correction of their development.

лизофосфатидная кислотарецепторы лизофосфатидной кислотыионные каналы с транзиторным рецепторным потенциаломбронхиальная астмаlysophosphatidic acidlysophosphatidic acid receptorstransient receptor potential channelsbronchial asthmaИсследование проводилось за счёт средств федерального бюджета в рамках государственного задания Фонда научных исследований.ReferencesKano K, Aoki J, Hla T. Lysophospholipid mediators inhealth and disease. Annu Rev Pathol. 2022; 17: 459-483. doi: 10.1146/annurev-pathol-050420-025929Kano K, AokiJ, Hla T. Lysophospholipid mediators inhealth and disease. Annu Rev Pathol. 2022; 17: 459-483. doi: 10.1146/annurev-pathol-050420-025929Xiang H, Lu Y, Shao M, Wu T. Lysophosphatidic acid receptors: Biochemical and clinical implications in different diseases. J Cancer. 2020; 11(12): 3519-3535. doi: 10.7150/jca.41841Xiang H, Lu Y, Shao M, Wu T. Lysophosphatidic acid receptors: Biochemical and clinical implications in different diseases. J Cancer. 2020; 11(12): 3519-3535. doi: 10.7150/jca.41841Jendzjowsky NG, Roy A, Wilson RJA. Asthmatic allergen inhalation sensitises carotid bodies to lysophosphatidic acid. JNeuroinflammation. 2021; 18(1): 191. doi: 10.1186/s12974-021-02241-9Jendzjowsky NG, Roy A, Wilson RJA. Asthmatic allergen inhalation sensitises carotid bodies to lysophosphatidic acid. JNeuroinflammation. 2021; 18(1): 191. doi: 10.1186/s12974-021-02241-9Jendzjowsky NG, Roy A, Iftinca M, Barioni NO, Kelly MM, Herrington BA, et al. PKCε stimulation of TRPV1 orchestrates carotid body responses to asthmakines. J Physiol. 2021; 599(4): 1335-1354. doi: 10.1113/JP280749Jendzjowsky NG, Roy A, Iftinca M, Barioni NO, Kelly MM, HerringtonBA, et al. PKCε stimulation of TRPV1 orchestrates carotid body responses to asthmakines. J Physiol. 2021; 599(4): 1335-1354. doi: 10.1113/JP280749Kondo M, Tezuka T, Ogawa H, Koyama K, Bando H, Azuma M, et al. Lysophosphatidic acid regulates the differentiation of Th2 cells and its antagonist suppresses allergic airway inflammation. Int Arch Allergy Immunol. 2021; 182: 1-13. doi: 10.1159/000509804KondoM, TezukaT, OgawaH, KoyamaK, BandoH, AzumaM, et al. Lysophosphatidic acid regulates the differentiation of Th2 cells and its antagonist suppresses allergic airway inflammation. Int Arch Allergy Immunol. 2021; 182: 1-13. doi: 10.1159/000509804Meduri B, Pujar GV, Durai Ananda Kumar T, Akshatha HS, Sethu AK, Singh M, et al. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development. Eur J Med Chem. 2021; 222: 113574. doi: 10.1016/j.ejmech.2021.113574Meduri B, Pujar GV, Durai Ananda Kumar T, Akshatha HS, Sethu AK, Singh M, et al. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development. Eur J Med Chem. 2021; 222: 113574. doi: 10.1016/j.ejmech.2021.113574Zhao J, Zhao Y. Lysophospholipids in lung inflammatory diseases. Adv Exp Med Biol. 2021; 1303: 373-391. doi: 10.1007/978-3-030-63046-1_20Zhao J, Zhao Y. Lysophospholipids in lung inflammatory diseases. Adv Exp Med Biol. 2021; 1303: 373-391. doi: 10.1007/978-3-030-63046-1_20Hernández-Araiza I, Morales-Lázaro SL, Canul-Sánchez JA, Islas LD, Rosenbaum T. Role of lysophosphatidic acid in ion channel function and disease. J Neurophysiol. 2018; 120(3): 1198-1211. doi: 10.1152/jn.00226.2018Hernández-Araiza I, Morales-Lázaro SL, Canul-Sánchez JA, Islas LD, Rosenbaum T. Role of lysophosphatidic acid in ion channel function and disease. J Neurophysiol. 2018; 120(3): 1198-1211. doi: 10.1152/jn.00226.2018Langedijk J, Araya EI, Barroso AR, Tolenaars D, Nazaré M, Belabed H, et al. An LPAR5 –antagonist that reduces nociception and increases pruriception. Front Pain Res (Lausanne). 2022; 3: 963174. doi: 10.3389/fpain.2022.963174Langedijk J, Araya EI, Barroso AR, Tolenaars D, Nazaré M, Belabed H, et al. An LPAR5 –antagonist that reduces nociception and increases pruriception. Front Pain Res (Lausanne). 2022; 3: 963174. doi: 10.3389/fpain.2022.963174Kytikova OY, Novgorodtseva TP, Denisenko YK, Naumov DE, Gvozdenko TA, Perelman JM. Thermosensory transient receptor potential ion channels and asthma. Biomedicines. 2021; 9(7): 816. doi: 10.3390/biomedicines9070816Kytikova OY, Novgorodtseva TP, Denisenko YK, Naumov DE, Gvozdenko TA, Perelman JM. Thermosensory transient receptor potential ion channels and asthma. Biomedicines. 2021; 9(7): 816. doi: 10.3390/biomedicines9070816Jordt SE. TRPA1: An asthma target with a zing. J Exp Med. 2021; 218(4): e20202507. doi: 10.1084/jem.20202507Jordt SE. TRPA1: An asthma target with a zing. J Exp Med. 2021; 218(4): e20202507. doi: 10.1084/jem.20202507Deng L, Ma P, Wu Y, Ma Y, Yang X, Li Y, et al. High and low temperatures aggravate airway inflammation of asthma: Evidence in a mouse model. Environ Pollut. 2020; 256: 113433. doi: 10.1016/j.envpol.2019.113433Deng L, Ma P, Wu Y, Ma Y, Yang X, Li Y, et al. High and low temperatures aggravate airway inflammation of asthma: Evidence in a mouse model. Environ Pollut. 2020; 256: 113433. doi: 10.1016/j.envpol.2019.113433Long L, Yao H, Tian J, Luo W, Yu X, Yi F, et al. Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough. Respir Res. 2020; 20: 112. doi: 10.1186/s12931-019-1077-zLong L, Yao H, Tian J, Luo W, Yu X, Yi F, et al. Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough. Respir Res. 2020; 20: 112. doi: 10.1186/s12931-019-1077-zMüller I, Alt P, Rajan S, Schaller L, Geiger F, Dietrich A. Transient receptor potential (TRP) channels in airway toxicity and disease: An update. Cells. 2022; 11(18): 2907. doi: 10.3390/cells11182907Müller I, Alt P, Rajan S, Schaller L, Geiger F, Dietrich A. Transient receptor potential (TRP) channels inairway toxicity anddisease: An update. Cells. 2022; 11(18): 2907. doi: 10.3390/cells11182907Li M, Fan X, Ji L, Fan Y, Xu L. Exacerbating effects of trimellitic anhydride in ovalbumin-induced asthmatic mice and the gene and protein expressions of TRPA1, TRPV1, TRPV2 in lung tissue. Int Immunopharmacol. 2019; 69: 159-168. doi: 10.1016/j.intimp.2019.01.038Li M, Fan X, Ji L, Fan Y, Xu L. Exacerbating effects of trimellitic anhydride in ovalbumin-induced asthmatic mice and the gene and protein expressions of TRPA1, TRPV1, TRPV2 in lung tissue. Int Immunopharmacol. 2019; 69: 159-168. doi: 10.1016/j.intimp.2019.01.038Wang C, Meng X, Meng M, Shi M, Sun W, Li X, et al. Oxidative stress activates the TRPM2-Ca2+-NLRP3 axis to promote PM2.5-induced lung injury of mice. Biomed Pharmacother. 2020; 130: 110481. doi: 10.1016/j.biopha.2020.110481Wang C, Meng X, Meng M, Shi M, Sun W, Li X, et al. Oxidative stress activates the TRPM2-Ca2+-NLRP3 axis to promote PM2.5-induced lung injury of mice. Biomed Pharmacother. 2020; 130: 110481. doi: 10.1016/j.biopha.2020.110481Rouadi PW, Idriss SA, Bousquet J, Laidlaw TM, Azar CR, Sulaiman Al-Ahmad M, еt al. WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways. World Allergy Organ J. 2021; 14(12): 100617. doi: 10.1016/j.waojou.2021.100617Rouadi PW, Idriss SA, Bousquet J, Laidlaw TM, Azar CR, Sulaiman Al-Ahmad M, еt al. WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways. World Allergy Organ J. 2021; 14(12): 100617. doi: 10.1016/j.waojou.2021.100617Reyes-García J, Carbajal-García A, Montaño LM. Transient receptor potential cation channel subfamily V (TRPV) and its importance in asthma. EurJ Pharmacol. 2022; 915: 174692. doi: 10.1016/j.ejphar.2021.174692Reyes-García J, Carbajal-García A, Montaño LM. Transient receptor potential cation channel subfamilyV (TRPV) anditsimpor tance in asthma. EurJ Pharmacol. 2022; 915: 174692. doi: 10.1016/j.ejphar.2021.174692Benítez-Angeles M, Morales-Lázaro SL, Juárez-González E, Rosenbaum T. TRPV1: Structure, endogenous agonists, and mechanisms. Int J Mol Sci. 2020; 21(10): 3421. doi: 10.3390/ijms21103421Benítez-Angeles M, Morales-Lázaro SL, JuárezGonzález E, Rosenbaum T. TRPV1: Structure, endogenous agonists, and mechanisms. Int J Mol Sci. 2020; 21(10): 3421. doi: 10.3390/ijms21103421Tigyi GL, Johnson LR, Lee SC, Norman DD, Szabo E, Balogh A, et al. Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential. J Lipid Res. 2019: 60(3); 464-474. doi: 10.1194/jlr.S091744Tigyi GL, Johnson LR, Lee SC, Norman DD, Szabo E, Balogh A, et al. Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential. J Lipid Res. 2019: 60(3); 464-474. doi: 10.1194/jlr.S091744Zulfikar S, Mulholland S, Adamali H, Barratt SL. Inhibitors of the autotaxin-lysophosphatidic acid axis and their potential in the treatment of interstitial lung disease: Current perspectives. Clin Pharmacol. 2020; 12: 97-108. doi: 10.2147/CPAA.S228362Zulfikar S, Mulholland S, Adamali H, Barratt SL. Inhibitors of the autotaxin-lysophosphatidic acid axis and their potential in the treatment of interstitial lung disease: Current perspectives. Clin Pharmacol. 2020; 12: 97-108. doi: 10.2147/CPAA.S228362Yaginuma S, Kawana H, Aoki J. Current knowledge on mammalian phospholipase A1, brief history, structures, biochemical and pathophysiological roles. Molecules. 2022; 27(8): 2487. doi: 10.3390/molecules27082487Yaginuma S, Kawana H, Aoki J. Current knowledge on mammalian phospholipase A1, brief history, structures, biochemical and pathophysiological roles. Molecules. 2022; 27(8): 2487. doi: 10.3390/molecules27082487Panagopoulou M, Fanidis D, Aidinis V, Chatzaki E. ENPP2 methylation in health and cancer. IntJ Mol Sci. 2021; 22(21): 11958. doi: 10.3390/ijms222111958Panagopoulou M, Fanidis D, Aidinis V, Chatzaki E. ENPP2 methylation in health and cancer. IntJ Mol Sci. 2021; 22(21): 11958. doi: 10.3390/ijms222111958Joshi L, Plastira I, Bernhart E, Reicher H, Triebl A, Köfeler HC, et al. Inhibition of autotaxin and lysophosphatidic acid receptor 5 attenuates neuroinflammation in LPS-activated BV-2 microglia and a mouse endotoxemia model. IntJ Mol Sci. 2021; 22(16); 8519. doi: 10.3390/ijms22168519Joshi L, Plastira I, Bernhart E, ReicherH, TrieblA, KöfelerHC, et al. Inhibition of autotaxin and lysophosphatidic acid receptor 5 attenuates neuroinflammation in LPS-activated BV-2 microglia and a mouse endotoxemia model. IntJ Mol Sci. 2021; 22(16); 8519. doi: 10.3390/ijms22168519Liu S, Paknejad N, Zhu L, Kihara Y, Ray M, Chun J, et al. Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate. Nat Commun. 2022; 13(1): 731. doi: 10.1038/s41467-022-28417-2Liu S, PaknejadN, Zhu L, Kihara Y, Ray M, Chun J, et al. Differential activation mechanisms oflipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate. Nat Commun. 2022; 13(1): 731. doi: 10.1038/s41467-022-28417-2Tran KC, Zhao J. Lysophosphatidic acid regulates Rho family of GTPases in lungs. Cell Biochem Biophys. 2021; 79(3): 493-496. doi: 10.1007/s12013-021-00993-yTran KC, Zhao J. Lysophosphatidic acid regulates Rho family of GTPases in lungs. Cell Biochem Biophys. 2021; 79(3): 493-496. doi: 10.1007/s12013-021-00993-yGu Q, Lee LY. TRP channels in airway sensory nerves. Neurosci Lett. 2021; 748: 135719. doi: 10.1016/j.neulet.2021.135719Gu Q, Lee LY. TRP channels in airway sensory nerves. Neurosci Lett. 2021; 748: 135719. doi: 10.1016/j.neulet.2021.135719Yelshanskaya MV, Sobolevsky AI. Ligand-binding sites in vanilloid-subtype TRP channels. Front Pharmacol. 2022; 13: 900623. doi: 10.3389/fphar.2022.900623Yelshanskaya MV, Sobolevsky AI. Ligand-binding sites in vanilloid-subtype TRP channels. Front Pharmacol. 2022; 13: 900623. doi: 10.3389/fphar.2022.900623Wang H, Cheng X, Tian J, Xiao Y, Tian T, Xu F, et al. TRPC channels: Structure, function, regulation and recent advances in small molecular probes. Pharmacol Ther. 2020; 209: 107497. doi: 10.1016/j.pharmthera.2020.107497Wang H, Cheng X, Tian J, Xiao Y, Tian T, Xu F, et al. TRPC channels: Structure, function, regulation and recent advances in small molecular probes. Pharmacol Ther. 2020; 209: 107497. doi: 10.1016/j.pharmthera.2020.107497Nam JH, Kim WK. The role of TRP channels in allergic inflammation and its clinical relevance. Curr Med Chem. 2020; 27(9): 1446-1468. doi: 10.2174/0929867326666181126113015Nam JH, Kim WK. The role of TRP channels in allergic inflammation and its clinical relevance. Curr Med Chem. 2020; 27(9): 1446-1468. doi: 10.2174/0929867326666181126113015Fine M, Li X. A structural overview of TRPML1 and the TRPML family. Handb Exp Pharmacol. 2023; 278: 181-198. doi: 10.1007/164_2022_602Fine M, Li X. A structural overview of TRPML1 and the TRPML family. Handb Exp Pharmacol. 2023; 278: 181-198. doi: 10.1007/164_2022_602Nadezhdin KD, Neuberger A, Trofimov YA, Krylov NA, Sinica V, Kupko N, et al. Structural mechanism of heat-induced opening of a temperature-sensitive TRP channel. Nat Struct Mol Biol. 2021; 28(7): 564-572. doi: 10.1038/s41594-021-00615-4Nadezhdin KD, Neuberger A, Trofimov YA, Krylov NA, Sinica V, Kupko N, et al. Structural mechanism of heat-induced opening of a temperature-sensitive TRP channel. Nat Struct Mol Biol. 2021; 28(7): 564-572. doi: 10.1038/s41594-021-00615-4Thapa D, Valente JS, Barrett B, Smith MJ, Argunhan F, Lee SY, et al. Dysfunctional TRPM8 signalling in the vascular response to environmental cold in ageing. Elife. 2021; 10: e70153. doi: 10.7554/eLife.70153Thapa D, Valente JS, Barrett B, Smith MJ, Argunhan F, Lee SY, et al. Dysfunctional TRPM8 signalling in the vascular response to environmental cold in ageing. Elife. 2021; 10: e70153. doi: 10.7554/eLife.70153Islas LD. Closing in on the heat-activation mechanisms of TRPV channels. J Physiol. 2021; 599(21): 4733-4734. doi: 10.1113/JP282347Islas LD. Closing in on the heat-activation mechanisms of TRPV channels. J Physiol. 2021; 599(21): 4733-4734. doi: 10.1113/JP282347Phan TX, Ton HT, Gulyás H, Pórszász R, Tóth A, Russo R, et al. TRPV1 expressed throughout the arterial circulation regulates vasoconstriction and blood pressure. JPhysiol. 2020; 598(24): 5639- 5659. doi: 10.1113/JP279909Phan TX, Ton HT, Gulyás H, Pórszász R, Tóth A, Russo R, et al. TRPV1 expressed throughout the arterial circulation regulates vasoconstriction andblood pressure. JPhysiol. 2020; 598(24): 5639- 5659. doi: 10.1113/JP279909Balestrini A, Joseph V, Dourado M, Reese RM, Shields SD, Rougé L, et al. A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. J Exp Med. 2021; 218: e20201637. doi: 10.1084/jem.20201637Balestrini A, Joseph V, Dourado M, Reese RM, Shields SD, Rougé L, et al. A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. J Exp Med. 2021; 218: e20201637. doi: 10.1084/jem.20201637Rapp E, Lu Z, Sun L, Serna SN, Almestica-Roberts M, Burrell KL, et al. Mechanisms and consequences of variable TRPA1 expression by airway epithelial cells: Effects of TRPV1 genotype and environmental agonists on cellular responses to pollutants in vitro and asthma. Environ Health Perspect. 2023; 131(2): 27009. doi: 10.1289/EHP11076Rapp E, Lu Z, Sun L, Serna SN, Almestica-Roberts M, Burrell KL, et al. Mechanisms and consequences of variable TRPA1 expression by airway epithelial cells: Effects of TRPV1 genotype and environmental agonists on cellular responses to pollutants in vitro and asthma. Environ Health Perspect. 2023; 131(2): 27009. doi: 10.1289/EHP11076Talavera K, Startek JB, Alvarez-Collazo J, Boonen B, Alpizar YA, Sanchez A, et al. Mammalian transient receptor potential TRPA1 channels: From structure to disease. Physiol Rev. 2020; 100(2): 725-803. doi: 10.1152/physrev.00005.2019Talavera K, Startek JB, Alvarez-Collazo J, Boonen B, Alpizar YA, Sanchez A, et al. Mammalian transient receptor potential TRPA1 channels: From structure to disease. Physiol Rev. 2020; 100(2): 725-803. doi: 10.1152/physrev.00005.2019Reese RM, Dourado M, Anderson K, Warming S, Stark KL, Balestrini A, et al. Behavioral characterization of a CRISPR-generated TRPA1 knockout rat in models of pain; itch; and asthma. Sci Rep. 2020; 10(1): 979. doi: 10.1038/s41598-020-57936-5Reese RM, Dourado M, Anderson K, Warming S, Stark KL, Balestrini A, et al. Behavioral characterization of a CRISPR-generated TRPA1 knockout rat in models of pain; itch; and asthma. Sci Rep. 2020; 10(1): 979. doi: 10.1038/s41598-020-57936-5Jentsch Matias de Oliveira JR, Amorim MA, André E. The role of TRPA1 and TRPV4 channels in bronchoconstriction and plasma extravasation in airways of rats treated with captopril. Pulm Pharmacol Ther. 2020; 65: 102004. doi: 10.1016/j.pupt.2021.102004Jentsch Matias de Oliveira JR, Amorim MA, André E. The role of TRPA1 and TRPV4 channels in bronchoconstriction and plasma extravasation in airways of rats treated with captopril. Pulm Pharmacol Ther. 2020; 65: 102004. doi: 10.1016/j.pupt.2021.102004Lee LY, Hsu CC, Lin YJ, Lin RL, Khosravi M. Interaction between TRPA1 and TRPV1: synergy on pulmonary sensory nerves. Pulm Pharmacol Ther. 2015; 35: 87-93. doi: 10.1016/j.pupt.2015.08.003Lee LY, Hsu CC, Lin YJ, Lin RL, Khosravi M. Interaction between TRPA1 and TRPV1: synergy on pulmonary sensory nerves. Pulm Pharmacol Ther. 2015; 35: 87-93. doi: 10.1016/j.pupt.2015.08.003Riemma MA, Cerqua I, Romano B, Irollo E, Bertolino A, Camerlingo R, et al. Sphingosine-1-phosphate/TGF-β axis drives epithelial mesenchymal transition in asthma-like disease. Br J Pharmacol. 2022; 179(8): 1753-1768. doi: 10.1111/bph.15754Riemma MA, Cerqua I, Romano B, Irollo E, Bertolino A, Camerlingo R, et al. Sphingosine-1-phosphate/TGF-β axis drives epithelial mesenchymal transition in asthma-like disease. Br J Pharmacol. 2022; 179(8): 1753-1768. doi: 10.1111/bph.15754Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021; 8(1): e001026. doi: 10.1136/bmjresp-2021-001026Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021; 8(1): e001026. doi: 10.1136/bmjresp-2021-001026KimSJ, MoonHG, ParkGY. The roles of autotaxin/lysophosphatidic acid in immune regulation and asthma. Biochim Biophys Acta Mol Cell Biol Lipids. 2020; 1865(5): 158641. doi: 10.1016/j.bbalip.2020.158641KimSJ, MoonHG, ParkGY. The roles of autotaxin/lysophosphatidic acid in immune regulation and asthma. Biochim Biophys Acta Mol Cell Biol Lipids. 2020; 1865(5): 158641. doi: 10.1016/j.bbalip.2020.158641Georas SN. LPA and autotaxin: Potential drug targets inasthma? Cell Biochem Biophys. 2021; 79(3): 445-448. doi: 10.1007/s12013-021-01023-7Georas SN. LPA and autotaxin: Potential drug targets inasthma? Cell Biochem Biophys. 2021; 79(3): 445-448. doi: 10.1007/s12013-021-01023-7Zhao Y, Hasse S, Vaillancourt M, Zhao C, Davis L, Boilard E, et al. Phospholipase A1 member A activates fibroblast-like synoviocytes through the autotaxin-lysophosphatidic acid receptor axis. IntJ Mol Sci. 2021; 22(23): 12685. doi: 10.3390/ijms222312685Zhao Y, Hasse S, Vaillancourt M, Zhao C, Davis L, Boilard E, et al. Phospholipase A1 member A activates fibroblast-like synoviocytes through the autotaxin-lysophosphatidic acid receptor axis. IntJ Mol Sci. 2021; 22(23): 12685. doi: 10.3390/ijms222312685Di Lollo V, Canciello A, Orsini M, Bernabò N, Ancora M, Di Federico M et al. Transcriptomic and computational analysis identified LPA metabolism, KLHL14 and KCNE3 as novel regulators of epithelial-mesenchymal transition. Sci Rep. 2020; 10(1): 4180. doi: 10.1038/s41598-020-61017-yDi Lollo V, Canciello A, Orsini M, Bernabò N, Ancora M, Di Federico M et al. Transcriptomic and computational analysis identified LPA metabolism, KLHL14 and KCNE3 as novel regulators of epithelial-mesenchymal transition. Sci Rep. 2020; 10(1): 4180. doi: 10.1038/s41598-020-61017-yWang L, Chitano P, Seow CY. Mechanopharmacology of Rho-kinase antagonism in airway smooth muscle and poten tial new therapy for asthma. Pharmacol Res. 2020; 159: 104995. doi: 10.1016/j.phrs.2020.104995Wang L, Chitano P, Seow CY. Mechanopharmacology of Rho-kinase antagonism in airway smooth muscle and poten tial new therapy for asthma. Pharmacol Res. 2020; 159: 104995. doi: 10.1016/j.phrs.2020.104995Falvey A, Duprat F, Simon T, Hugues-Ascery S, Conde SV, Glaichenhaus N, et al. Electrostimulation of the carotid sinus nerve in mice attenuates inflammation via glucocorticoid receptor on myeloid immune cells. J Neuroinflammation. 2020; 17(1): 368. doi: 10.1186/s12974-020-02016-8Falvey A, Duprat F, Simon T, Hugues-Ascery S, Conde SV, GlaichenhausN, et al. Electrostimulation ofthe carotid sinus nerve in mice attenuates inflammation via glucocorticoid receptor on myeloid immune cells. J Neuroinflammation. 2020; 17(1): 368. doi: 10.1186/s12974-020-02016-8Llona-Minguez S, Ghassemian A, Helleday T. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. Prog Lipid Res. 2015; 58: 51-75. doi: 10.1016/j.plipres.2015.01.004Llona-Minguez S, Ghassemian A, Helleday T. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. Prog Lipid Res. 2015; 58: 51-75. doi: 10.1016/j.plipres.2015.01.004Lee YJ, Im DS. Efficacy comparison of LPA2 antagonist H2L5186303 and agonist GRI977143 on ovalbumin-induced allergic asthma in BALB/c mice. Int J Mol Sci. 2022; 23(17): 9745. doi: 10.3390/ijms23179745Lee YJ, Im DS. Efficacy comparison of LPA2 antagonist H2L5186303 and agonist GRI977143 on ovalbumin-induced allergic asthma in BALB/c mice. Int J Mol Sci. 2022; 23(17): 9745. doi: 10.3390/ijms23179745Jia Y, Li Y, XuXD, Tian Y, ShangH. Design anddevelopment of autotaxin inhibitors. Pharmaceuticals (Basel). 2021; 14(11): 1203. doi: 10.3390/ph14111203Jia Y, Li Y, XuXD, Tian Y, ShangH. Design anddevelopment of autotaxin inhibitors. Pharmaceuticals (Basel). 2021; 14(11): 1203. doi: 10.3390/ph14111203Cuozzo JW, Clark MA, Keefe AD, Kohlmann A, Mulvihill M, Ni H, et al. Novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis: A clinical candidate discovered using DNA-encoded chemistry. J Med Chem. 2020; 63(14): 7840-7856. doi: 10.1021/acs.jmedchem.0c00688Cuozzo JW, Clark MA, Keefe AD, Kohlmann A, Mulvihill M, Ni H, et al. Novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis: A clinical candidate discovered using DNA-encoded chemistry. J Med Chem. 2020; 63(14): 7840-7856. doi: 10.1021/acs.jmedchem.0c00688Nie C, Zhang L, Chen X, Li Y, Ha F, Li H. Autotaxin: An early warning biomarker for acute-on-chronic liver failure. J Clin Transl Hepatol. 2020; 8: 240. doi: 10.14218/JCTH.2020.00045Nie C, Zhang L, Chen X, Li Y, Ha F, Li H. Autotaxin: An early warning biomarker for acute-on-chronic liver failure. J Clin Transl Hepatol. 2020; 8: 240. doi: 10.14218/JCTH.2020.00045Alioli C, Demesmay L, Peyruchaud O, Machuca-Gayet I. Autotaxin/lysophosphatidic acid axis: From bone biology to bone disorders. IntJ Mol Sci. 2022; 23(7): 3427. doi: 10.3390/ijms23073427Alioli C, Demesmay L, Peyruchaud O, Machuca-Gayet I. Autotaxin/lysophosphatidic acid axis: From bone biology to bone disorders. IntJ Mol Sci. 2022; 23(7): 3427. doi: 10.3390/ijms23073427Fukui M, Tsutsumi T, Yamamoto-Mikami A, Morito K, TakahashiN, TanakaT, et al. Distinct contributions oftwo choline-producing enzymatic activities to lysophosphatidic acid production in human amniotic fluid from pregnant women inthe second trimester andafter parturition. Prostaglandins Other Lipid Mediat. 2020; 150: 106471.Fukui M, Tsutsumi T, Yamamoto-Mikami A, Morito K, TakahashiN, TanakaT, et al. Distinct contributions oftwo choline-producing enzymatic activities to lysophosphatidic acid production in human amniotic fluid from pregnant women inthe second trimester andafter parturition. Prostaglandins Other Lipid Mediat. 2020; 150: 106471.Isshiki T, ShimizuH, SakamotoS, YamasakiA, Miyoshi S, Nakamura Y, et al. Serum autotaxin levels inchronic disease andacute exacerbation of fibrosing interstitial lung disease. ERJ Open Res. 2022; 8(2): 00683-2021. doi: 10.1183/23120541.00683-2021Isshiki T, ShimizuH, SakamotoS, YamasakiA, Miyoshi S, Nakamura Y, et al. Serum autotaxin levels inchronic disease andacute exacerbation of fibrosing interstitial lung disease. ERJ Open Res. 2022; 8(2): 00683-2021. doi: 10.1183/23120541.00683-2021Abdel-Magid AF. Therapeutic potential of autotaxin inhibitors in treatment of interstitial lung diseases. ACS Med Chem Lett. 2020; 11(11): 2075-2076. doi: 10.1021/acsmedchemlettAbdel-Magid AF. Therapeutic potential of autotaxin inhibitors in treatment of interstitial lung diseases. ACS Med Chem Lett. 2020; 11(11): 2075-2076. doi: 10.1021/acsmedchemlettLei H, Li Z, Li T, Wu H, Yang J, Yang X, et al. Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model. Bioorg Chem. 2022; 120: 105590. doi: 10.1016/j.bioorg.2021.105590Lei H, Li Z, Li T, Wu H, Yang J, Yang X, et al. Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model. Bioorg Chem. 2022; 120: 105590. doi: 10.1016/j.bioorg.2021.105590

The authors declare that there are no conflicts of interest present.